Informação sobre produto
- 6-cyano-4-(N-ethylsulfonyl-N-methylamino)-3-hydroxy-2,2-dimethylchromane
- Chromanol 239B
- Ethanesulfonamide, N-(6-cyano-3,4-dihydro-3-hydroxy-2,2-dimethyl-2H-1-benzopyran-4-yl)-N-methyl-, trans-
- Ethanesulfonamide, N-[(3R,4S)-6-cyano-3,4-dihydro-3-hydroxy-2,2-dimethyl-2H-1-benzopyran-4-yl]-N-methyl-, rel-
- N-(6-cyano-3-hydroxy-2,2-dimethyl-3,4-dihydro-2H-chromen-4-yl)-N-methylethanesulfonamide
- N-[(3R,4R)-6-cyano-3-hydroxy-2,2-dimethyl-3,4-dihydro-2H-chromen-4-yl]-N-methylethanesulfonamide
- N-[(3R,4S)-6-cyano-3-hydroxy-2,2-dimethyl-3,4-dihydro-2H-chromen-4-yl]-N-methylethanesulfonamide
- Trans-N-[6-Cyano-3,4-Dihydro-3-Hydroxy-2,2-Dimethyl-2H-1-Benzopyran-4-Yl]-N-Methyl-Ethanesulfonamide
- rel-N-[(3R,4S)-6-Cyano-3,4-dihydro-3-hydroxy-2,2-dimethyl-2H-1-benzopyran-4-yl]-N-methylethanesulfonamide
Chromagnol is a drug that inhibits the enzyme protein kinase C (PKC). It has been shown to have inhibitory properties on cardiac muscle cells and whole-cell recordings of heart cells. Chromagnol has also been shown to affect the function of bowel disease, including papillary muscle. Chromagnol has been shown to have effects on cardiac and atrial tissue. This drug may be a potential treatment for autoimmune diseases, such as multiple sclerosis, or other diseases that are caused by PKC overactivity. The mechanisms of action are not fully understood but it is believed that chromanol binds to the cytosolic Ca2+ ion channel, preventing it from opening and releasing Ca2+, which leads to an increase in intracellular Ca2+.
Propriedades químicas
Consulta técnica sobre: 3D-FC166930 Chromagnol
Se desejar solicitar um orçamento ou fazer uma encomenda, por favor, adicione os produtos ao seu carrinho e depois solicite um orçamento ou encomenda a partir do carrinho. É mais rápido, mais barato e poderá beneficiar-se dos descontos e outras vantagens disponíveis.